Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Oct;10(5):500-508.
doi: 10.2174/138920309789351949.

Light chain amyloidosis - current findings and future prospects

Affiliations

Light chain amyloidosis - current findings and future prospects

Elizabeth M Baden et al. Curr Protein Pept Sci. 2009 Oct.

Abstract

Systemic light chain amyloidosis (AL) is one of several protein misfolding diseases and is characterized by extracellular deposition of immunoglobulin light chains in the form of amyloid fibrils [1]. Immunoglobulin (Ig) proteins consist of two light chains (LCs) and two heavy chains (HCs) that ordinarily form a heterotetramer which is secreted by a plasma cell. In AL, however, a monoclonal plasma cell population produces an abundance of a pathogenic LC protein. In this case, not all of the LCs pair with the HCs, and free LCs are secreted into circulation. The LC-HC dimer is very stable, and losing this interaction may result in an unstable LC protein [2]. Additionally, somatic mutations are thought to cause amyloidogenic proteins to be less stable compared to non-amyloidogenic proteins [3-5], leading to protein misfolding and amyloid fibril formation. The amyloid fibrils cause tissue damage and cell death, leading to patient death within 12-18 months if left untreated [6]. Current therapies are harsh and not curative, including chemotherapy and autologous stem cell transplants. Studies of protein pathogenesis and fibril formation mechanisms may lead to better therapies with an improved outlook for patient survival. Much has been done to determine the molecular factors that make a particular LC protein amyloidogenic and to elucidate the mechanism of amyloid fibril formation. Anthony Fink's work, particularly with discerning the role of intermediates in the fibril formation pathway, has made a remarkable impact in the field of amyloidosis research. This review provides a general overview of the current state of AL research and also attempts to capture the most recent ideas and knowledge generated from the Fink laboratory.

PubMed Disclaimer

Figures

Fig. (1)
Fig. (1)
Immunoglobulin light chain dimer of a multiple myeloma protein from the κI germline shows the typical structure and dimer interface observed in these proteins (1WTL). a) Two LC monomers (green and blue), each consisting of 9 anti-parallel β-strands (labeled A-G), dimerize. The boxed area indicates the 40-44 loop region discussed in the text that may play a role in amyloidogenicity in AL. b) This view highlights the LC dimer interface in the center. Amino acids from both subunits extend into this interface and interact through hydrogen bonding networks.
Fig. (2)
Fig. (2)
Model for protein folding and misfolding with aggregation occurring at the intermediate step. Various factors can destabilize proteins to aid in the formation of either amorphous aggregates or fibrils based on the results from Dr. Fink’s laboratory.

Similar articles

Cited by

References

    1. Buxbaum JN. Trends Biochem Sci. 2003;28:585–92. - PubMed
    1. Stevens FJ, Westholm FA, Solomon A, Schiffer M. Proc Natl Acad Sci U S A. 1980;77:1144–8. - PMC - PubMed
    1. Wall J, Schell M, Murphy C, Hrncic R, Stevens FJ, Solomon A. Biochemistry. 1999;38:14101–8. - PubMed
    1. Stevens PW, Raffen R, Hanson DK, Deng YL, Berrios-Hammond M, Westholm FA, Murphy C, Eulitz M, Wetzel R, Solomon A, et al. Protein Sci. 1995;4:421–32. - PMC - PubMed
    1. Kim Y, Wall JS, Meyer J, Murphy C, Randolph TW, Manning MC, Solomon A, Carpenter JF. J Biol Chem. 2000;275:1570–4. - PubMed

Publication types